THE BISOPROLOL — A HIGH SELECTIVE BETA-BLOCKER ACCORDING TO EVIDENCE BASED MEDICINE
https://doi.org/10.20996/1819-6446-2010-6-1-103-107
Abstract
Data of the evidence based medicine about bisoprolol treatment of patients with cardiovascular diseases (arterial hypertension, ischemic heart disease, chronic heart failure, rhythm disorders) are presented. Implementation of bisoprolol generics as well as bisoprolol usage in smoking cardiovascular patients is also discussed.
About the Authors
Yu. V. Lukina
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per. 10, Moscow, 101990
Russian Federation
Petroverigsky per. 10, Moscow, 101990
S. Yu. Martsevich
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per. 10, Moscow, 101990
Russian Federation
Petroverigsky per. 10, Moscow, 101990
References
1. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств.3-е изд., перераб. и доп. М.: МИА; 2005.
2. Dahlöf B., Devereux R., Kjeldsen S. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized study against atenolol. Lancet 2002;359(9311):995-1003.
3. Dahlöf B., Sever P., Wedel H. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366(9489):895-906.
4. Hypertension: management of hypertension in adults in primary care. NICE/BHS, 2006. Sudbury, UK: The Lavenham Press Ltd.; 2006. Available on http://www.nice.org.uk/nicemedia/pdf/HypertensionGuide.pdf
5. Herlitz J., Dellborg M., Karlson B.W. et al. Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge. Cardiovasc Drugs Ther 2000;14(6):589-95.
6. Weiner L., Frithz G. Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension. A dose-ranging study with parallel groups. Eur J Clin Pharmacol 1986;29(5):517-21.
7. Weiner L., Frithz G. Dose-effect relationship and longterm effects of bisoprolol in mild to moderate hypertension J Cardiovasc Pharmacol 1986; 8(Suppl 11): S106-12.
8. Haasis R., Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double–blind study (BISOMET). Eur Heart J 1987;8 Suppl M:103-13.
9. Gosse P., Roudaut R., Herrero G., Dallocchio M. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16(Suppl 5):S145-150
10. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994;90(4):1765-3.
11. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353(9146):9-13.
12. Willenheimer R., Silke B. Possible clinical implications of the Cardiac Insufficiency Bisoprolol (CIBIS) III trial. Br J Cardiol 2005;12(6):448-54.
13. de Muinck E.D., Buchner-Moell D., van de Ven L.L., Lie K.I. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a Multicenter International Randomized Study of Angina pectoris (MIRSA). J Cardiovasc Pharmacol 1992;19(6):870-5
14. Weber F., Schneider H., von Arnim T., Urbaszek W. Heart rate variability and ischaemia in patients with coronary heart disease and stable angina pectoris; influence of drug therapy and prognostic value. TIBBS Investigators Group. Total Ischemic Burden Bisoprolol Study. Eur Heart J 1999; 20 (1): 38–50.
15. Ferguson J.D., Ormerod O., Lenox–Smith A.J. Bisoprolol alone and in combination with amlodipine ore nifedipine in the treatment of chronic stable angina. Int J Clin Pract 2000;54(6):360–3.
16. Plevan A., Lehmann G., Ndrepepa G. et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J 2001;22(16):1504-10.
17. Singh B.N. CIBIS, MERIT-HF, and COPERNICUS trial outcomes: do they complete the chapter on beta-adrenergic blockers as antiarrhytmic and antifibrillatory drugs? J Cardiovasc Pharmacol Ther 2001;6(2):107-10.
18. Bühler F.R., Berglund G., Anderson O.K. et al. Double-blind comparison of the cardioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986;8 Suppl 11:S122-7.
19. Лукина Ю.В., Марцевич С.Ю,Шальнова С.А., КутишенкоН.П.Антиангинальная эффективность β-адреноблокаторов у курящих и некурящих больных ишемической болезнью сердца. Врач 2004;(9):36-42
Review
For citations:
Lukina Yu.V., Martsevich S.Yu. THE BISOPROLOL — A HIGH SELECTIVE BETA-BLOCKER ACCORDING TO EVIDENCE BASED MEDICINE. Rational Pharmacotherapy in Cardiology. 2010;6(1):103-107. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-1-103-107
Views: 1046
Email this article 